Most Read Articles
Stephen Padilla, 3 days ago
Diabetic patients in a decompensated state and who develop type 2 myocardial infarction (MI) have an increased risk for mortality and major adverse cardiac events (MACE), according to a new study. In addition, these patients are potentially at risk for undiagnosed coronary artery disease.
5 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 6 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
5 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.

Tofacitinib improves hair regrowth in alopaecia areata

27 Jun 2018

JAK inhibitor tofacitinib appear to have therapeutic potential to halt hair loss in patients with alopaecia areata, a recent study has shown.

The open-label pilot study included 12 moderate-to-severe alopaecia areata patients, of whom eight achieved the primary efficacy endpoint of 50-percent hair regrowth from baseline. Tofacitinib therapy duration ranged from 6–18 months. The mean time to reach the primary endpoint was 32 weeks.

Of the five patients with either alopaecia universalis or alopaecia totalis, four participants achieved 50-percent har regrowth.

Participants who reached the primary efficacy endpoint during the first 6–18 months were followed for an additional 6 months off-treatment. Six patients showed variable hair shedding after treatment conclusion, two of whom showed the initial signs of shedding within 3–4 weeks. Excellent durability of treatment response was reported in three participants.

Mean baseline scores in the Dermatology Life Quality Index was 6.5±5 points, which dropped to 5.2±6.7 at 3 months and to 6±6.9 points after the 6-month treatment regimen.

In terms of treatment safety, the most common adverse event was upper respiratory infections of any grade, reported in 91.6 percent (n=11) of the patients. This was followed by increased bowel movement frequency (33.3 percent; n=4) and blood on urinalysis (33.3 percent; n=4). One patient with a history of hypertension discontinued treatment due to hypertensive urgency.

For the study, treatment outcomes were measured using the Severity in Alopecia Tool score. Hair regrowth as a continuous variable was evaluated using Canfield photography.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 3 days ago
Diabetic patients in a decompensated state and who develop type 2 myocardial infarction (MI) have an increased risk for mortality and major adverse cardiac events (MACE), according to a new study. In addition, these patients are potentially at risk for undiagnosed coronary artery disease.
5 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 6 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
5 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.